This Review discusses the mechanisms and origins of cardiovascular risks associated with prostate cancer therapies, mainly focusing on differences between gonadotropin-releasing hormone agonists and antagonists. Cardiovascular risks associated with all other available prostate cancer treatments are also discussed.
- Steven Tisseverasinghe
- Marwan Tolba
- Tamim Niazi
